An Open-label, Phase 2 Study of ACP-196 (acalabrutinib) in Subjects With Mantle Cell Lymphoma

Trial Identifier: ACE-LY-004
Sponsor: AcertaPharma
Start Date: March 2015
Primary Completion Date: December 2020
Study Completion Date: September 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Monash, AU
AU Sydney, AU, 2139
AU Wodonga, AU, 3690
BE Brugge, BE, 8000
BE Bruxelles, BE, 1200
BE Bruxelles, BE, 1000
BE Liège, BE, 4000
BE Yvoir, BE, 5530
CZ Prague, CZ, 100 34, CZ
ES Badalona, ES, 8916
ES Pamplona, ES, 31008
FR Angers, FR, 49033
FR Caen, FR, 14033
FR Clermond Ferrand, FR, 63003
FR Creteil, FR, 94010
FR Dijon, FR, 21000
FR Grenoble Cedex 09, FR, 38043
FR La Roche - Sure-Yon, FR, 85925
FR Lille, FR, 59000
FR Montpellier, FR, 34295
FR Nantes, FR, 44093
FR Paris, FR, 75015
FR Paris cedex 13, FR, 75651
FR Pessac, FR, 33604
FR Pierre-Benite, FR, 69310
FR Rennes, FR, 35033
FR Rouen, FR, 76038
FR Saint-Priest-En-Jarez, FR, 42270
FR Strasbourg Cedex, FR, 67098
FR Toulouse, FR, 31100
FR Tours, FR, 37000
FR Vandoeuvre-les-Nancy, FR, 54500
GB Cardiff, GB, CF14 4XW
GB Leeds, GB, LS9 7TF
GB Leicester, GB, LE1 7RH
GB Nottingham, GB, NG5 1PB
GB Oxford, GB, 0X3 7LE
GB Plymouth, GB, PL6 8DH
GB Southampton, GB, SO16 6YD
IT Bologna, IT, 40138
IT Meldola, IT, 47014
IT Milano, IT, 20132
IT Novara, IT, 28100
NL Amsterdam, NL, 1105 AZ
NL Maastricht, NL, 6202 AZ
NL Rotterdam, NL, 3062 PA
PL Kraków, PL, 30-727
PL Lodz, PL, 93-510
PL Olsztyn, PL, 10-228
US, FL Tampa, FL, US, 33612
US, IL Chicago, IL, US, 60612
US, IL Niles, IL, US, 60714
US, IL Peoria, IL, US, 61615
US, MA Boston, MA, US, 2215
US, NJ Hackensack, NJ, US, 07601
US, NY New York, NY, US, 10021
US, TX Houston, TX, US, 77030
US, WA Seattle, WA, US, 98109